Zosuquidar (LY335979) 3HCl: Selective P-gp Inhibitor for Multidrug Resistance Reversal

Executive Summary: Zosuquidar (LY335979) 3HCl is a potent and selective P-glycoprotein (P-gp) inhibitor, designed to reverse multidrug resistance (MDR) in cancer by blocking ATP-dependent drug efflux (APExBIO). The compound restores chemosensitivity in vitro and in vivo without altering the pharmacokinetics of co-administered drugs (Sun et al., 2025). Zosuquidar has demonstrated efficacy in murine MDR leukemia and human non-small cell lung carcinoma (NSCLC) xenograft models. Clinical trials report effective P-gp inhibition with low toxicity in combination chemotherapy regimens. The compound is distributed by APExBIO as SKU A3956 and is soluble in DMSO, with optimal storage at -20°C.

Biological Rationale

P-glycoprotein (P-gp, ABCB1) is an ATP-dependent efflux transporter expressed in the plasma membrane of various tissues, including the brain, liver, kidney, and tumor cells. P-gp actively exports structurally diverse xenobiotics and chemotherapeutic agents, reducing their intracellular accumulation. Overexpression of P-gp is a primary mechanism of MDR in many cancers, notably acute myeloid leukemia (AML) and non-Hodgkin's lymphoma (Disrupting Multidrug Resistance). The clinical consequence is diminished response to a broad spectrum of anticancer drugs. According to recent pharmacokinetic studies, modulation of P-gp can significantly alter the distribution and effectiveness of chemotherapeutics without affecting their metabolism by cytochrome P450 enzymes (Sun et al., 2025). While earlier articles such as "Precision P-gp Inhibitor for MDR" focus on basic selectivity, this dossier updates with direct clinical and in vivo benchmarks.

Mechanism of Action of Zosuquidar (LY335979) 3HCl

Zosuquidar (LY335979) 3HCl competitively inhibits the substrate binding site of P-gp, preventing efflux of chemotherapeutic agents such as vinblastine, doxorubicin, etoposide, and paclitaxel from cancer cells (APExBIO). The compound binds with high affinity (K_i in the low micromolar range) to the drug-binding pocket of P-gp, blocking ATP hydrolysis and subsequent substrate transport. This inhibition restores intracellular drug accumulation and chemosensitivity, as confirmed in multiple cell line models. Zosuquidar does not significantly inhibit other ABC transporters (e.g., MRP1, BCRP) at effective concentrations, providing high substrate specificity (P-gp Inhibitor for Multidrug Resistance). This mechanism is further clarified compared to "Advanced Strategies for Overcoming MDR", which focused on molecular signaling rather than competitive inhibition as the primary mode.

Evidence & Benchmarks

• In vitro, Zosuquidar at 1–2 µM restores sensitivity to vinblastine, doxorubicin, etoposide, and paclitaxel in P-gp overexpressing leukemia cells, increasing their cytotoxic efficacy by up to 12-fold (Sun et al., 2025, DOI).
• In vivo, co-administration of Zosuquidar with vincristine prolongs survival in murine models of MDR leukemia (median survival extension: 47%, p<0.01) without altering plasma pharmacokinetics of vincristine (Sun et al., 2025, DOI).
• Clinical phase I/II studies report effective P-gp inhibition and minimal added toxicity when Zosuquidar is combined with CHOP chemotherapy in relapsed/refractory non-Hodgkin’s lymphoma (Kabanov & Batrakova, 2018, PubMed).
• Zosuquidar does not significantly inhibit cytochrome P450 enzymes at effective concentrations (in vitro liver microsome studies; Sun et al., 2025).
• Transporter studies (Caco-2 and transfected HEK293 cells) confirm Zosuquidar's selective inhibition of P-gp-mediated efflux, with no major impact on MRP1 or BCRP substrates at ≤2 µM (Sun et al., 2025, DOI).

Applications, Limits & Misconceptions

Zosuquidar (LY335979) 3HCl is primarily used as a research tool and adjunct in preclinical and translational oncology to study and reverse P-gp-mediated MDR. It enables evaluation of chemotherapeutic efficacy in P-gp-overexpressing cell lines and tumor models. In clinical research, Zosuquidar has been combined with standard regimens (e.g., CHOP, vinorelbine) in AML, non-Hodgkin's lymphoma, and NSCLC (the A3956 kit).

For a hands-on protocol focus, see "P-gp Inhibitor for Multidrug Resistance", which this article extends by providing new clinical outcome data and highlighting selectivity boundaries.

Common Pitfalls or Misconceptions

• Zosuquidar does not reverse resistance mediated by non-P-gp mechanisms (e.g., MRP1, BCRP overexpression).
• No direct cytotoxicity: Zosuquidar alone does not kill cancer cells; its effect is adjuvant to chemotherapeutics.
• Pharmacokinetic neutrality: Zosuquidar does not alter the plasma levels or metabolism of co-administered drugs at standard doses.
• Species specificity: Efficacy and selectivity may vary between human and rodent P-gp isoforms.
• Stability: Long-term storage of Zosuquidar solutions is not recommended due to degradation at room temperature or above.

Workflow Integration & Parameters

Product information: Zosuquidar (LY335979) 3HCl is supplied by APExBIO (SKU A3956) as a solid. It is readily soluble in DMSO at ≥10 mM (APExBIO). Store below -20°C. For in vitro assays, typical working concentrations are 0.5–2 µM. For in vivo studies, dosing regimens must be optimized for species and tissue distribution, with reference to published pharmacokinetic data (Sun et al., 2025). Zosuquidar is compatible with standard chemotherapeutic agents and does not require special administration routes.

In cell-based MDR reversal assays, Zosuquidar is added 30–60 minutes prior to chemotherapeutic challenge. For animal models, pre-treatment or co-administration is preferred. Solutions should be freshly prepared; avoid repeated freeze-thaw cycles. Refer to "Advanced Strategies for Overcoming MDR" for more detailed in vivo protocol contrasts, as this guide focuses on integration with pharmacokinetic endpoints.

Conclusion & Outlook

Zosuquidar (LY335979) 3HCl is a validated, highly selective P-gp inhibitor with demonstrated utility in reversing MDR in vitro, in vivo, and in early-phase clinical settings. Its specificity for P-gp, lack of intrinsic cytotoxicity, and pharmacokinetic neutrality distinguish it from earlier MDR modulators. Ongoing research will clarify its role in combination regimens for hematological and solid tumors. For more information or to order, see the official APExBIO Zosuquidar product page.